InMed Pharmaceuticals Inc. (INM) shares are jumping in premarket trading Tuesday after the company announced a merger agreement with Mentari Therapeutics. The deal is designed to combine Mentari's migraine prevention pipeline with InMed's public market presence, potentially speeding up development of treatments for a condition that affects over 1 billion people worldwide.
The merger brings together complementary drug programs, which could be a big step forward for both companies. The combined entity will operate as Mentari Therapeutics and trade on the Nasdaq Capital Market under a new ticker symbol.
This strategic move is backed by a concurrent private placement of $290 million, which should keep the lights on through 2028. That's a nice cushion for a biotech company, where cash burn is always a concern.
Mentari's pipeline includes two key candidates: MT-001, with Phase 2a proof-of-concept data expected in 2028, and MT-002, with Phase 1 healthy volunteer data expected in 2027. These drugs target different but complementary pathways in migraine pathophysiology, aiming to address the significant unmet need for people suffering from chronic and episodic migraine.
Under the merger terms, pre-merger InMed shareholders are expected to own about 1.51% of the combined company, which is projected to have a pro forma equity value of roughly $421.4 million. The transaction has been approved by both companies' boards and is expected to close in the second half of 2026.
As for the stock: InMed shares were up 120.41% at $1.50 at the time of publication Tuesday, according to market data.
